Compare Dow Jones Industrial Average ETF (DIA) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Illumina, Inc. — how do they compare? Dow Jones Industrial Average ETF trades at $538, while Illumina, Inc. trades at $193.06 (market cap $29.12B). Which is the better fit depends on your goals.
| DIA | ILMN | |
|---|---|---|
52-Week High | $542.79 | $205.10 |
52-Week Low | $444.64 | $91.00 |
Market Cap | — | $29.12B |
Sector | — | Health |
Enterprise Value | — | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA trades at $539.70, up 0.28% today, with a bullish technical signal from moving averages and key support at $538. Recent dividends include $1.41 paid in July 2026, reflecting income stability. The stock benefits from broad market momentum, as highlighted by ETF inflows into U.S. equities (ETF Trends, August 7, 2026).
Outlook remains positive due to technical strength and defensive positioning in blue-chip ETFs, but overbought RSI levels near 86 suggest short-term caution. Risks include market volatility from Fed policy and geopolitical tensions, though institutional support provides a cushion for long-term holders.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
